GLUE
Monte Rosa Therapeutics, Inc.
Price Chart
Latest Quote
$20.71
+2.04 (+10.93%)
Current Price
| Previous Close | $18.67 |
| Open | $18.41 |
| Day High | $20.98 |
| Day Low | $18.38 |
| Volume | 1,731,828 |
Stock Information
| Shares Outstanding | 84.48M |
| Total Debt | $39.06M |
| Cash Equivalents | $666.22M |
| Revenue | $42.95M |
| Net Income | $-130.01M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.75B |
| EPS (TTM) | $-1.48 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.12B |
| Sales | $42.95M |
| Income | $-130.01M |
| Book/sh | $6.19 |
| Cash/sh | $7.89 |
| Employees | 187 |
Financial Ratios
| Quick Ratio | 9.44 |
| Current Ratio | 9.54 |
| Debt/Eq | 7.49 |
Returns & Margins
| ROA | -16.41% |
| ROE | -32.62% |
| Gross Margin | -238.54% |
| Operating Margin | -1188.46% |
Ownership
| Insider Ownership | 0.58% |
| Institutional Ownership | 113.20% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.41 |
| P/S | 40.73 |
| P/B | 3.35 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $32.33 |
Technical Indicators
| SMA20 | $18.18 |
| SMA50 | $18.75 |
| SMA200 | $15.99 |
| RSI | 68.99 |
| ATR | 1.2886 |
| Shares Float | 53.00M |
| Short Float | 19.24% |
| Short Ratio | 20.99 |
| Volatility | 1.60 |
| Rel Volume | 1.51 |
Performance History
| Week | +14.29% |
| Month | +9.69% |
| Quarter | +37.79% |
| 6 Months | +30.83% |
| YTD | +35.27% |
| Year | +347.30% |
| 3 Years | +180.24% |
| 10 Years | -2.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $20.71 | 1,752,300 |
| 2026-06-22 | $18.67 | 1,790,300 |
| 2026-06-18 | $18.31 | 2,507,700 |
| 2026-06-17 | $18.41 | 1,184,500 |
| 2026-06-16 | $17.76 | 795,100 |
| 2026-06-15 | $18.12 | 745,300 |
| 2026-06-12 | $18.24 | 1,092,000 |
| 2026-06-11 | $17.10 | 1,386,700 |
| 2026-06-10 | $16.52 | 873,100 |
| 2026-06-09 | $16.61 | 832,800 |
| 2026-06-08 | $17.00 | 2,046,100 |
| 2026-06-05 | $16.37 | 950,300 |
| 2026-06-04 | $17.36 | 729,600 |
| 2026-06-03 | $17.59 | 882,100 |
| 2026-06-02 | $17.74 | 973,700 |
| 2026-06-01 | $19.67 | 1,005,500 |
| 2026-05-29 | $19.71 | 1,279,600 |
| 2026-05-28 | $19.39 | 1,184,300 |
| 2026-05-27 | $19.17 | 571,500 |
| 2026-05-26 | $19.20 | 697,500 |
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1Ã and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
đ° Latest News
Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy
Insider Monkey âĸ 2026-06-03T18:00:19Z
Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention
Simply Wall St. âĸ 2026-05-10T00:24:31Z
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T15:15:05Z
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-06T00:30:10Z
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Motley Fool âĸ 2026-04-21T17:53:49Z
Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story
Simply Wall St. âĸ 2026-03-21T11:07:15Z
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting
MT Newswires âĸ 2026-03-17T12:56:18ZMonte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans
MarketBeat âĸ 2026-03-17T12:40:37Z
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-03-17T12:25:01Z
Monte Rosa Therapeutics: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-17T11:33:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $123,672,000 | $75,622,000 | $0 | $0 |
| Operating Revenue | $123,672,000 | $75,622,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $177,880,000 | $156,734,000 | $143,311,000 | $112,384,000 |
| Other Income Expense | $1,543,000 | $416,000 | $-1,037,000 | $119,000 |
| Net Non Operating Interest Income Expense | $12,942,000 | $10,566,000 | $9,334,000 | $3,764,000 |
| Operating Expense | $177,880,000 | $156,734,000 | $143,311,000 | $112,384,000 |
| General And Administrative Expense | $36,380,000 | $35,171,000 | $32,039,000 | $27,323,000 |
| Other Non Operating Income Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Net Interest Income | $12,942,000 | $10,566,000 | $9,334,000 | $3,764,000 |
| Interest Income | $12,942,000 | $10,566,000 | $9,334,000 | $3,764,000 |
| Normalized Income | $-40,125,796 | $-73,028,640 | $-134,532,770 | $-108,620,000 |
| Net Income From Continuing And Discontinued Operation | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Total Operating Income As Reported | $-54,208,000 | $-81,112,000 | $-143,311,000 | $-112,384,000 |
| Net Income Common Stockholders | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Net Income | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Net Income Including Noncontrolling Interests | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Net Income Continuous Operations | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Pretax Income | $-39,723,000 | $-70,130,000 | $-135,014,000 | $-108,501,000 |
| Special Income Charges | $59,000 | $0 | $24,000 | $109,000 |
| Interest Income Non Operating | $12,942,000 | $10,566,000 | $9,334,000 | $3,764,000 |
| Operating Income | $-54,208,000 | $-81,112,000 | $-143,311,000 | $-112,384,000 |
| Per Share | ||||
| Diluted EPS | $-0.59 | $-1.18 | $-2.63 | $-2.30 |
| Basic EPS | $-0.59 | $-1.18 | $-2.63 | $-2.30 |
| Other | ||||
| Tax Effect Of Unusual Items | $43,204 | $87,360 | $-217,770 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-47,395,000 | $-73,407,000 | $-136,052,000 | $-108,758,000 |
| Total Unusual Items | $1,543,000 | $416,000 | $-1,037,000 | $119,000 |
| Total Unusual Items Excluding Goodwill | $1,543,000 | $416,000 | $-1,037,000 | $119,000 |
| Reconciled Depreciation | $8,356,000 | $8,121,000 | $6,222,000 | $3,745,000 |
| EBITDA (Bullshit earnings) | $-45,852,000 | $-72,991,000 | $-137,089,000 | $-108,639,000 |
| EBIT | $-54,208,000 | $-81,112,000 | $-143,311,000 | $-112,384,000 |
| Diluted Average Shares | $65,543,723 | $61,507,446 | $51,396,961 | $47,227,370 |
| Basic Average Shares | $65,543,723 | $61,507,446 | $51,396,961 | $47,227,370 |
| Diluted NI Availto Com Stockholders | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Tax Provision | $-1,097,000 | $2,570,000 | $338,000 | $0 |
| Gain On Sale Of Ppe | $59,000 | $0 | $24,000 | $109,000 |
| Gain On Sale Of Security | $1,484,000 | $416,000 | $-1,061,000 | $10,000 |
| Research And Development | $141,500,000 | $121,563,000 | $111,272,000 | $85,061,000 |
| Selling General And Administration | $36,380,000 | $35,171,000 | $32,039,000 | $27,323,000 |
| Other Gand A | $13,405,000 | $13,018,000 | $12,391,000 | $11,936,000 |
| Salaries And Wages | $22,975,000 | $22,153,000 | $19,648,000 | $15,387,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $233,056,000 | $222,936,000 | $179,250,000 | $271,413,000 |
| Total Assets | $448,659,000 | $438,732,000 | $303,755,000 | $342,389,000 |
| Total Non Current Assets | $55,474,000 | $61,292,000 | $67,543,000 | $66,503,000 |
| Other Non Current Assets | $5,102,000 | $4,978,000 | $4,932,000 | $4,596,000 |
| Current Assets | $393,185,000 | $377,440,000 | $236,212,000 | $275,886,000 |
| Other Current Assets | $4,481,000 | $5,118,000 | $3,294,000 | $4,444,000 |
| Receivables | $11,600,000 | $173,000 | $505,000 | $7,656,000 |
| Other Receivables | $11,600,000 | $173,000 | $505,000 | $7,656,000 |
| Cash Cash Equivalents And Short Term Investments | $377,104,000 | $372,149,000 | $232,413,000 | $262,826,000 |
| Cash And Cash Equivalents | $129,883,000 | $224,254,000 | $128,101,000 | $54,912,000 |
| Restricted Cash | - | - | $0 | $960,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $39,191,000 | $42,715,000 | $46,039,000 | $47,001,000 |
| Long Term Debt And Capital Lease Obligation | $34,794,000 | $39,001,000 | $42,877,000 | $43,874,000 |
| Current Debt And Capital Lease Obligation | $4,397,000 | $3,714,000 | $3,162,000 | $3,127,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $215,603,000 | $215,796,000 | $124,505,000 | $70,976,000 |
| Total Non Current Liabilities Net Minority Interest | $151,391,000 | $58,850,000 | $77,913,000 | $45,407,000 |
| Non Current Deferred Liabilities | $111,332,000 | $16,147,000 | $32,323,000 | $0 |
| Current Liabilities | $64,212,000 | $156,946,000 | $46,592,000 | $25,569,000 |
| Other Current Liabilities | $1,578,000 | $3,354,000 | $1,671,000 | $5,020,000 |
| Current Deferred Liabilities | $29,571,000 | $117,232,000 | $17,678,000 | $0 |
| Payables And Accrued Expenses | $18,668,000 | $24,426,000 | $16,488,000 | $11,798,000 |
| Payables | $3,550,000 | $17,215,000 | $11,152,000 | $7,862,000 |
| Accounts Payable | $3,550,000 | $17,215,000 | $11,152,000 | $7,862,000 |
| Equity | ||||
| Common Stock Equity | $233,056,000 | $222,936,000 | $179,250,000 | $271,413,000 |
| Total Equity Gross Minority Interest | $233,056,000 | $222,936,000 | $179,250,000 | $271,413,000 |
| Stockholders Equity | $233,056,000 | $222,936,000 | $179,250,000 | $271,413,000 |
| Gains Losses Not Affecting Retained Earnings | $-3,827,000 | $-3,356,000 | $-2,724,000 | $-1,752,000 |
| Other Equity Adjustments | $-3,827,000 | $-3,356,000 | $-2,724,000 | $-1,752,000 |
| Retained Earnings | $-477,214,000 | $-438,588,000 | $-365,888,000 | $-230,536,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $0 | $0 |
| Other | ||||
| Ordinary Shares Number | $65,543,723 | $61,507,446 | $50,140,233 | $49,323,531 |
| Share Issued | $65,543,723 | $61,507,446 | $50,140,233 | $49,445,802 |
| Tangible Book Value | $233,056,000 | $222,936,000 | $179,250,000 | $271,413,000 |
| Invested Capital | $233,056,000 | $222,936,000 | $179,250,000 | $271,413,000 |
| Working Capital | $328,973,000 | $220,494,000 | $189,620,000 | $250,317,000 |
| Capital Lease Obligations | $39,191,000 | $42,715,000 | $46,039,000 | $47,001,000 |
| Total Capitalization | $233,056,000 | $222,936,000 | $179,250,000 | $271,413,000 |
| Additional Paid In Capital | $714,090,000 | $664,874,000 | $547,857,000 | $503,696,000 |
| Capital Stock | $7,000 | $6,000 | $5,000 | $5,000 |
| Common Stock | $7,000 | $6,000 | $5,000 | $5,000 |
| Employee Benefits | $5,265,000 | $3,702,000 | $2,713,000 | $1,533,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $5,265,000 | $3,702,000 | $2,713,000 | $1,533,000 |
| Non Current Deferred Revenue | $111,332,000 | $16,147,000 | $32,323,000 | $0 |
| Long Term Capital Lease Obligation | $34,794,000 | $39,001,000 | $42,877,000 | $43,874,000 |
| Current Deferred Revenue | $29,571,000 | $117,232,000 | $17,678,000 | $0 |
| Current Capital Lease Obligation | $4,397,000 | $3,714,000 | $3,162,000 | $3,127,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $9,998,000 | $8,220,000 | $7,593,000 | $5,624,000 |
| Current Accrued Expenses | $15,118,000 | $7,211,000 | $5,336,000 | $3,936,000 |
| Net PPE | $50,372,000 | $56,314,000 | $62,611,000 | $61,907,000 |
| Accumulated Depreciation | $-27,613,000 | $-20,364,000 | $-12,244,000 | $-6,251,000 |
| Gross PPE | $77,985,000 | $76,678,000 | $74,855,000 | $68,158,000 |
| Leases | $23,669,000 | $22,387,000 | $20,893,000 | $2,660,000 |
| Construction In Progress | $118,000 | $64,000 | $924,000 | $12,013,000 |
| Other Properties | $51,408,000 | $51,872,000 | $50,887,000 | $52,598,000 |
| Machinery Furniture Equipment | $2,790,000 | $2,355,000 | $2,151,000 | $887,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $247,221,000 | $147,895,000 | $104,312,000 | $207,914,000 |
| Treasury Shares Number | - | - | - | $122,271 |
| Preferred Stock | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-27,498,000 | $38,008,000 | $-62,843,000 | $-105,377,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-22,798,000 | $41,996,000 | $-43,802,000 | $-92,466,000 |
| Cash Flow From Continuing Operating Activities | $-22,798,000 | $41,996,000 | $-43,802,000 | $-92,466,000 |
| Operating Gains Losses | $-59,000 | - | $107,000 | $-109,000 |
| Investing Activities | ||||
| Capital Expenditure | $-4,700,000 | $-3,988,000 | $-19,041,000 | $-12,911,000 |
| Investing Cash Flow | $-101,833,000 | $-44,452,000 | $88,801,000 | $-219,219,000 |
| Cash Flow From Continuing Investing Activities | $-101,833,000 | $-44,452,000 | $88,801,000 | $-219,219,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-357,000 | $-641,000 | $-116,000 | - |
| Issuance Of Capital Stock | $24,250,000 | $944,000 | $0 | $20,055,000 |
| Financing Cash Flow | $30,351,000 | $98,892,000 | $27,492,000 | $20,466,000 |
| Cash Flow From Continuing Financing Activities | $30,351,000 | $98,892,000 | $27,492,000 | $20,466,000 |
| Net Common Stock Issuance | $23,893,000 | $303,000 | $-116,000 | $20,055,000 |
| Common Stock Issuance | $24,250,000 | $944,000 | $0 | $20,055,000 |
| Net Other Financing Charges | - | $47,001,000 | $-116,000 | $-364,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| End Cash Position | $134,837,000 | $229,117,000 | $132,681,000 | $60,190,000 |
| Beginning Cash Position | $229,117,000 | $132,681,000 | $60,190,000 | $351,409,000 |
| Changes In Cash | $-94,280,000 | $96,436,000 | $72,491,000 | $-291,219,000 |
| Proceeds From Stock Option Exercised | $6,458,000 | $51,588,000 | $27,608,000 | $775,000 |
| Common Stock Payments | $-357,000 | $-641,000 | $-116,000 | - |
| Net Investment Purchase And Sale | $-97,133,000 | $-40,464,000 | $107,780,000 | $-206,417,000 |
| Sale Of Investment | $279,542,000 | $189,897,000 | $210,931,000 | $178,000,000 |
| Purchase Of Investment | $-376,675,000 | $-230,361,000 | $-103,151,000 | $-384,417,000 |
| Net PPE Purchase And Sale | $-4,700,000 | $-3,988,000 | $-18,979,000 | $-12,802,000 |
| Purchase Of PPE | $-4,700,000 | $-3,988,000 | $-19,041,000 | $-12,911,000 |
| Change In Working Capital | $-9,189,000 | $91,397,000 | $72,466,000 | $-2,134,000 |
| Change In Other Working Capital | $7,490,000 | $82,217,000 | $60,177,000 | $-107,000 |
| Change In Payables And Accrued Expense | $-5,856,000 | $10,436,000 | $9,315,000 | $287,000 |
| Change In Accrued Expense | $7,852,000 | $4,184,000 | $3,557,000 | $1,031,000 |
| Change In Payable | $-13,708,000 | $6,252,000 | $5,758,000 | $-744,000 |
| Change In Account Payable | $-13,708,000 | $6,252,000 | $5,758,000 | $-744,000 |
| Change In Prepaid Assets | $604,000 | $-1,588,000 | $1,077,000 | $-2,127,000 |
| Change In Receivables | $-11,427,000 | $332,000 | $1,897,000 | $-187,000 |
| Stock Based Compensation | $18,865,000 | $18,126,000 | $16,669,000 | $11,664,000 |
| Amortization Of Securities | $-2,145,000 | $-2,948,000 | $-3,914,000 | $-1,945,000 |
| Depreciation Amortization Depletion | $8,356,000 | $8,121,000 | $6,222,000 | $3,745,000 |
| Depreciation And Amortization | $8,356,000 | $8,121,000 | $6,222,000 | $3,745,000 |
| Depreciation | $8,356,000 | $8,121,000 | $6,222,000 | $3,745,000 |
| Gain Loss On Sale Of PPE | $-59,000 | $0 | $-24,000 | $-109,000 |
| Net Income From Continuing Operations | $-38,626,000 | $-72,700,000 | $-135,352,000 | $-108,501,000 |
| Sale Of PPE | - | $0 | $62,000 | $109,000 |
| Gain Loss On Investment Securities | - | - | $131,000 | - |
| Other Non Cash Items | - | - | - | $4,814,000 |
Fetched: 2026-06-17